ArticleJournal of virology2002
Analysis of deletion mutants indicates that the 2A polypeptide of hepatitis A virus participates in virion morphogenesis.
Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 66 citations in OpenAlex.
- Genetic variability of hepatitis A virus genotype I strains in Bulgaria, 2011-2023.BMC infectious diseases · 2026Article
- Identification and Genomic Characterization of Two Novel Hepatoviruses in Shrews from Yunnan Province, China.Viruses · 2024Article
- Nonlytic Quasi-Enveloped Hepatovirus Release Is Facilitated by pX Protein Interaction with the E3 Ubiquitin Ligase ITCH.Journal of virology · 2022Article
- Nonlytic cellular release of hepatitis A virus requires dual capsid recruitment of the ESCRT-associated Bro1 domain proteins HD-PTP and ALIX.PLoS pathogens · 2022Article
- Pathogenicity and virulence of hepatitis A virus.Virulence · 2021Review
- Gangliosides are essential endosomal receptors for quasi-enveloped and naked hepatitis A virus.Nature microbiology · 2020Article
- Hepatitis A virus structural protein pX interacts with ALIX and promotes the secretion of virions and foreign proteins through exosome-like vesicles.Journal of extracellular vesicles · 2020Article
- Hepatitis A Virus Genome Organization and Replication Strategy.Cold Spring Harbor perspectives in medicine · 2018Review
- Evolutionary Origins of Enteric Hepatitis Viruses.Cold Spring Harbor perspectives in medicine · 2018Review
- Redundant Late Domain Functions of Tandem VP2 YPXJournal of virology · 2018Article
- A Novel Marsupial Hepatitis A Virus Corroborates Complex Evolutionary Patterns Shaping the Genus Hepatovirus.Journal of virology · 2018Article
- Potent neutralization of hepatitis A virus reveals a receptor mimic mechanism and the receptor recognition site.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Structures and Corresponding Functions of Five Types of Picornaviral 2A Proteins.Frontiers in microbiology · 2017Review
- Article
- Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis.Journal of clinical and translational hepatology · 2016Review
- Solubility as a limiting factor for expression of hepatitis A virus proteins in insect cell-baculovirus system.Memorias do Instituto Oswaldo Cruz · 2016Article
- Human hepatitis A virus is united with a host of relations.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Naked Viruses That Aren't Always Naked: Quasi-Enveloped Agents of Acute Hepatitis.Annual review of virology · 2014Article
- Molecular biology and inhibitors of hepatitis A virus.Medicinal research reviews · 2014Review
- Picornavirus morphogenesis.Microbiology and molecular biology reviews : MMBR · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unlike all other picornaviruses, the primary cleavage of the hepatitis A virus (HAV) polyprotein occurs at the 2A/2B junction and is carried out by the only proteinase encoded by the virus, 3C(pro). The resulting P1-2A capsid protein precursor is subsequently cleaved by 3C(pro) to generate VP0, VP3, and VP1-2A, which associate as pentamers. An unidentified cellular proteinase acting at the VP1/2A junction releases the mature capsid protein VP1 from VP1-2A later in the morphogenesis process. Although these aspects of polyprotein processing are well characterized, the function of 2A is unknown. To study its role in the viral life cycle, we assessed the infectivity of synthetic, genome-length RNAs containing 11 different in-frame deletions in the 2A region. Deletions in the N-terminal 40% of 2A abolished infectivity, whereas deletions in the C-terminal 60% resulted in viruses with a small-focus replication phenotype. C-terminal deletions in 2A had no effect on RNA replication kinetics under one-step growth conditions, nor did they have an effect on capsid protein synthesis and 3C(pro)-mediated processing. However, C-terminal deletions in 2A altered the VP1/2A cleavage, resulting in accumulation of uncleaved VP1-2A precursor in virions and possibly accounting for a delay in the appearance of infectious particles with these mutants, as well as a fourfold decrease in specific infectivity of the virus particles. When the capsid proteins were expressed from recombinant vaccinia viruses, the N-terminal part of 2A was required for efficient cleavage of the P1-2A precursor by 3C(pro) and assembly of structural precursors into pentamers. These data indicate that the N-terminal domain of 2A must be present as a C-terminal extension of P1 for folding of the capsid protein precursor to allow efficient 3C(pro)-mediated cleavages and to promote pentamer assembly, after which cleavage at the VP1/2A junction releases the mature VP1 protein, a process that appears to be necessary to produce highly infectious particles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.